Screener
Dyne Therapeutics, Inc. DYN EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Dyne Therapeutics, Inc.’s reported figures.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
FAQ
- What is Dyne Therapeutics, Inc.'s EBITDA?
- Dyne Therapeutics, Inc. (DYN) reported EBITDA of -$124.73M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s EBITDA changed year-over-year?
- Dyne Therapeutics, Inc.'s EBITDA decreased by 2.3% year-over-year, from -$121.87M to -$124.73M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s EBITDA has grown at a 33.0% compound annual growth rate (CAGR), from -$148.95M to -$466.16M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Dyne Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude